Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans.
Studies of the immune response of patients following major injury have identified significant abnormalities, some of which may be due to the effects of endotoxin. To evaluate the effect of endotoxin on the immune system without conflicting variables, we studied 18 normal, healthy male volunteers each on two occasions. In one study, Escherichia coli endotoxin was administered intravenously at a dose of 4 ng/kg. In the other, saline was given. Blood for immune function studies was obtained at either 0, 4, or 24 hr (seven volunteers), 0, 1, and 4 hr (five volunteers), or 0, 4, and 6 hr (six volunteers) postinfusion. Peripheral blood mononuclear cells (PBMC) were isolated and adjusted to the same concentration. Measurements following endotoxin infusion were compared with those of the same volunteers following saline infusion and with those from normal ambulatory laboratory volunteers. Interleukin 1 (IL-1) production by adherent cells was significantly reduced at 1 hr post endotoxin infusion. Significant decreases in number of mononuclear cells, response to phytohemagglutinin (PHA), and production of IL-2 and IL-1 were observed by 4 hr after endotoxin infusion. No significant changes in percentages of monocytes, lymphocytes, or CD3, CD4, or CD8 lymphocytes were observed at any time. By 24 hr postinfusion all values had returned to normal or, in some cases, supranormal levels. Response to PHA by PBMC from volunteers 4 hr following endotoxin was completely restored by in vitro addition of recombinant human IL-2 but was only marginally improved by IL-1. In vitro addition of indomethacin to PBMC cultures responding to PHA reduced the suppression observed after in vivo endotoxin but also was not as effective as IL-2. In a fourth study, seven volunteers were treated as above either with two doses (800 mg each) of the cyclooxygenase inhibitor ibuprofen before endotoxin infusion or with ibuprofen alone. Ibuprofen pretreatment completely restored the PBMC response to PHA to normal and caused a significant decrease in the endotoxin-induced suppression of IL-2 production. However, the decrease in circulating PBMC number and adherent cell secretion of IL-1 was not affected by inhibition of the cyclooxygenase pathway. These results suggest that endotoxin has immunomodulatory effects on both adherent mononuclear-cell and T-lymphocyte function and that more than one mechanism is involved.
Rodrick
M L
ML
Department of Surgery, Brigham & Women's Hospital, Boston, Massachusetts 02115.
Moss
N M
NM
Grbic
J T
JT
Revhaug
A
A
O'Dwyer
S T
ST
Michie
H R
HR
Gough
D B
DB
Dubravec
D
D
Manson
J M
JM
Saporoschetz
I B
IB
D000328:Adult; D004731:Endotoxins / Q000008:administration & dosage / Q000276:immunology*; D004926:Escherichia coli / Q000276:immunology; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage; D007111:Immunity, Cellular / Q000276:immunology*; D007262:Infusions, Intravenous; D007375:Interleukin-1 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D009000:Monocytes / Q000276:immunology; D010835:Phytohemagglutinins; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology
D004731:Endotoxins; D007375:Interleukin-1; D007376:Interleukin-2; D010835:Phytohemagglutinins; C044101:endotoxin, Escherichia coli; D011451:Prostaglandin-Endoperoxide Synthases; D007052:Ibuprofen